Auro Laboratories Limited has submitted the Outcome of the Board Meeting held on August 14, 2026

Aura Laboratories Limited 314,T.V.lndustrial Estate, S.K.Ahire Marg Worli,Mumbai - 400 030. India Tel.:+ 91 22 6663 5456 Fax:+ 9122 6663 5460 Email : auro@aurolabs.com Web : www.aurolabs.com Reg.Off/ Mfg.Unit: K-56, M.I.D.C. Tarapur, Dist. Palghar, Maharashtra -401506 CIN No. L33125MH1989PLC051910 Date: August 14, 2026 Listing Department BSELimited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001. Ref: Security Code NoJISIN: 530233/ INE292C01011 Sub: Outcome of the meeting of Board of Directors dated August 14, 2026. Dear Sir / Madam, Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting to be held on (i.e. Friday, August 14, 2026), has transacted the following business: 1. Approved the Unaudited Financial Results of the Company for the quarter ended Jw1e 30, 2026 as recommended by the Audit Committee. In this regard, we are enclosing herewith: • Unaudited Financial Results for the quarter ended June 30, 2026. • Limited Review Report received from the Statutory Auditors of the Company. The Meeting of the Board of Directors commenced at 03:30 p.m. and concluded at 04:30 p.m. The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in due course. Kindly take the above information on records. Thanking You, Yours Faithfully, For AURO LABORATORIES LIMITED SIDDHARTHA DEORAH WHOLE TWE DIRECTOR DIN: 00230796 Encl.: A/a AURO LABOR AT ORIES LIMITED CIN NO.:-L33125MH1989PLC051910 Regd. Office: K -56 M.1.D.C INDUSTRIAL AREA, TARAPUR BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com ANNEXURE -1 (Rs_ In Lakhs except EPS PART-1: STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE OUARTER ENDED 30TH JUNE 2026 Quarter Ended Year Ended No. Particulars 30-06-2026 31-03-2026 30--06-2026 31.03-2026 (Unaudited) (Audited) (Unaudited) (Audited) 876.81 983_25 2TT.42 3,073.98 1 Revenue from Operations 10.83 66.38 41.65 200.93 2 Other Income 887.64 1,049.63 319.07 3,274.91 3 Total Income (1 + 2) 4 Expenses a. Cost of raw material consumed 412.66 372.65 124.82 1,427.66 b. Purchase of Stock-in-trade 1.50 0.00 . 1.43 c. Changes in inventories of finished goods, work-In-progress (241_67} (168.90) (34.TT) (823.00) and stock in trade 125.91 199.52 49.11 586.21 d. Employee benefits expense e. Finance Cost 136.85 148.74 28.07 425.29 f. Depreciation and amortisation expenses 91.36 90.35 27.41 281.02 g. other Expenses 247.99 247.33 134.97 881.07 Total Expenses (4) 774.59 889.68 329.62 2,TT9.67 6 Profit/ (Lon) before exceptional Items and tax (3 :1: 4) 113.05 159.95 (10.55) 495.23 . 14.42 . 14.42 6 Exceptional items 7 Profit/ (LO$$) before tax (5 t 6) 113.05 145.63 (10.55) 480.82 8 Tax expense . . . - (a) Current tax expenses for current year (b) Deferred tax 8.49 48.46 . 127.53 9 Profit I (Loss) for the period from continuing operation (7:t 8) 104.56 97.07 (10.55) 353.2.9 . - . - 10 Profit I (Lo11S) for discontinuing operations . - - . 11 Tax expense of discontinuing operations . - - . 12 Profit/ (Loss) for discontinuing operation (after tax) (10 ! 11) 13 Profit/ (Loss) for the period (after tax) (9 t 12) 104.56 97.07 (10.55) 353.29 14 Other Comprehensive Income A. Items that wlll not be reclasslfed subsequently to profit or loss (I) Items that wlll not be reclasslfled to profit or loss 0.22 (0.13) 44.80 (15.96) (ii) Income tax relating to items that will not be reclassified to profit or loss (0.03) 0.02 (11.28) 0.62 . - . B. Items that will be reclasslfed subsequently to profit or loss . . . (I) Items that will be reclassified to profit or loss . (ii) Income tax relating to Items that will be reclassified to profit or loss - . - - Total other comprehensive income /(loss), net of tax (14) 0.19 (0.11) 33.52 (15.34) 15 Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and 104.75 96.96 2.2.97 337.95 other comprehensive Income (after tax)] (13 ± 14) 16 Paid-up equity share capital (Face value of Rs. 10 each) 623.25 623.25 623.25 623.2S - . . 4,011.50 17 Other Equity 18 Earnings per share (EPS) (Face Value -Rs. 10 per Equity Shares) 1.68 1.56 (0.17) S.67 (a) Basic (b) Diluted 1.68 1.56 (0.17) 5.67 Notes on financial results:• 1 The Un-Audited Standalone Financial Results have been prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standards (lndAS 34). the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, [SEBI (LODR) Regulations, 2015] as amended. 2 The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors In their meeting held on 14th August,2026. 3 In accordance with Regulation 33 of the SEBI (LODR) Regulatlons, 2015, the above Un-Audited Standalone Financial Results of the Company are posted on Company's website (www.aurolabs.com) and on the website of BSE Limited (www.bselndia.com) where the Company's shares are listed. 4 Toe Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind AS 108 on operating 5 The figures for the previous quarter ended 30th June,2025 were audited by the erstwhile auditors and the same has been relied upon. 6 Figures for the previous Period/ Year have been re-grouped/ reworked/ re-arranged wherever necessary, to make them comparable. For and on behalf of the Board of Directors (Q ~o) Slddhartha Oeorah 1 ..J MUMBAI C. ) Whole Time Director 0 INDIA .S: DIN: 00230796 \ ~ * '?):::; /y - 0 Place: Mumbai oate<I: 14tn August, 2026 B. L. DASHARDA & ASSOCIATES CA< CHARTERED ACCOUNTANTS IND I A INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015 Review Report to The Board of Directors, AURO LABORATORIES LTD, Mumbai. 1) We have reviewed the accompanying Statement of Unaudited Standalone Financial Result of Auro Laboratories Ltd (' 'the Company'') for the quarter ended 30th June, 2026("the Statement"), being submitted by Company to the Stock Exchange viz. BSE Limited ("BSE") pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation"), read with SEBI Circular No. CIR/CFD/CMDl/44/2019 dated 29thMarch, 2019 ("the Circular"). 2) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, "Interim Financial Reporting", (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review. 3) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review ofI nterim Financial Information Performed by the Independent Auditor ofE ntity "("the Standard''), issued by the Institute of Chartered Accountants oflndia. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. 4) Based on our r [Showing first 8,000 characters — download PDF for full document]